Investor.bridgebio.com

  1. Home
  2. Investor.bridgebio.com

BridgeBio BridgeBio Pharma Grows Pipeline to 20+ Genetic …

WEB-New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder SAN …

Actived: Just Now

URL: https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-grows-pipeline-20-genetic-medicines-four-assets

BridgeBio BridgeBio Pharma Announces Progress in its KRAS …

WEBPALO ALTO, Calif., Oct. 12, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and …

Category:  Health Go Health

BridgeBio BridgeBio Pharma and Kyowa Kirin Announce …

WEB- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive upfront …

Category:  Health Go Health

BridgeBio BridgeBio announces consistently positive results from

WEB- Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p<0.0001)- 58% of ties in Finkelstein-Schoenfeld (F-S) primary analysis …

Category:  Health Go Health

BridgeBio BridgeBio Pharma, Inc. Appoints Pioneering National …

WEBPALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and …

Category:  Health Go Health

BridgeBio BridgeBio Pharma Presents Updated Results from …

WEB- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change …

Category:  Health Go Health

BridgeBio BridgeBio Pharma’s Affiliate QED Therapeutics and …

WEBPivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated …

Category:  Health Go Health

BridgeBio BridgeBio Pharma, Inc. and the University of Colorado

WEBPALO ALTO, Calif. and DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus …

Category:  Medical Go Health

BridgeBio BridgeBio Pharma Announces Submission of New Drug

WEB- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of …

Category:  Health Go Health

BridgeBio Pharma to Participate in November Investor Events

WEBBridgeBio Pharma to Participate in November Investor Events. 11.09.2022 at 7:30 AM EST. PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio …

Category:  Health Go Health

BridgeBio BridgeBio Pharma and Sentynl Therapeutics Receive …

WEB- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A …

Category:  Health Go Health

j.p. morgan healthcare conference BridgeBio Pharma

WEBThe Investor Relations website contains information about BridgeBio Pharma's business for stockholders, potential investors, and financial analysts.

Category:  Health Go Health

BridgeBio BridgeBio Pharma Launches CoA Therapeutics To …

WEBPALO ALTO, Calif., June 13, 2018 /PRNewswire/ — BridgeBio Pharma today announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small …

Category:  Health Go Health

BridgeBio Burjeel Holdings to Launch Rare Disease Research

WEB– Project ‘NADER’ is intended to span multiple phases, starting from mapping rare diseases in the UAE and wider region through innovative risk assessment …

Category:  Health Go Health

Adora Ndu, Pharm.D., J.D. Management BridgeBio Pharma

WEBAdora Ndu has served as our Chief Regulatory Affairs Officer since January 2022. Prior to joining BridgeBio, she held various leadership positions at BioMarin Pharmaceutical …

Category:  Health Go Health

JP Morgan Presentation

WEBAcoramidis is well-positioned for success in the ATTR-CM market. ATTR is a $3B global market today, growing to $10-$15B. Acoramidis is a 2nd generation TTR stabilizer that …

Category:  Health Go Health

BridgeBio BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase …

WEB- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and …

Category:  Health Go Health

CALIBRATE: A Phase 3, Randomized, Open-Label Study …

WEBCALIBRATE is a multi-center, randomized, open-label, two-arm, global Phase 3 study with a long-term extension (LTE) designed to evaluate the efficacy and safety of encaleret …

Category:  Health Go Health

Michael Henderson, M.D. Management BridgeBio Pharma

WEBMichael Henderson, M.D. has served as our Chief Business Officer since January 2020. Prior to that, he served as our Senior Vice President, Asset Acquisition, Strategy and …

Category:  Health Go Health

Top Categories

 › Appendicitis

 › Headaches

 › Gout

 › Women's Health

 › Thyroid

 › Sleep

 › Skin

 › Sexual Health

 › Senior Health

 › Pregnancy

 › Oral Health

 › Neurology

 › Migraine

 › Mental Health

 › Men's Health

 › Menopause

 › Medications

 › Lung Conditions

 › Infectious Disease

 › HIV/AIDS

Popular Searched

 › Universal health care download

 › Lcmc health st charles

 › Kidney healthcare of texas

 › Icon portal wb health

 › Pam health hospital beaver pa

 › Sutter health job search

 › Ut austin health and wellbeing

 › Does mhealth still work

 › Top speech language pathologist offering healthcare in miami

 › Terrell county health department

Recently Searched

 › Trinity health lacks cancer center

 › Defense health agency appointment portal

 › Healthy chicken fried steak

 › Top family health insurance plans

 › Replenish health and wellness huntington

 › Public health in colorado

 › Alchemy health and wellness coaching

 › Erie county health department dental

 › Lancet global health viewpoint

 › Nexus mods npc health